1 Identification of actionable genetic variants in 4,198 Scottish volunteers from the Viking Genes research

2 cohort and implementation of return of results

- 3
- 4 Shona M. Kerr,^{1*}, Lucija Klaric,^{1*} Marisa D. Muckian,^{2,3} Kiera Johnston,² Camilla Drake,¹ Mihail Halachev,¹
- 5 Emma Cowan,^{4,5} Lesley Snadden,^{4,5} John Dean,⁵ Sean L. Zheng,^{6,7,8} Prisca K. Thami,^{6,7} James S. Ware,^{6,7,8}
- 6 Gannie Tzoneva,⁹ Alan R. Shuldiner,⁹ Zosia Miedzybrodzka^{4,5} and James F. Wilson^{+1,2,10}
- 7
- ¹MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Cancer, Western General
- 9 Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
- ²Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8
- 11 9AG, UK.
- ³Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel
- 13 Street, London WC1E 7HT, UK.
- ⁴Department of Medical Genetics, Ashgrove House, NHS Grampian, Aberdeen, AB25 2ZA, UK.
- ⁵Medical Genetics Group, University of Aberdeen, Polwarth Building, Aberdeen, AB25 2ZD, UK.
- ⁶National Heart and Lung Institute, Imperial College London, London, UK.
- ¹⁷ ⁷MRC Laboratory of Medical Sciences, Imperial College London, London, UK.
- ⁸Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
- ⁹Regeneron Genetics Center, Tarrytown, NY, USA.
- ¹⁰Centre for Genomic and Experimental Medicine, University of Edinburgh, Institute of Genetics and
- 21 Cancer, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
- 22
- 23 * These authors contributed equally
- 24 + Correspondence: jim.wilson@ed.ac.uk

25 Abstract

26	The benefits of returning clinically actionable genetic results to participants in research cohorts are
27	accruing, yet such a genome-first approach is challenging. Here, we describe the return of such results in
28	two founder populations from Scotland. Between 2005 and 2015, we recruited >4,000 adults with
29	grandparents from Orkney and Shetland into the Viking Genes research cohort. Return of genetic data
30	was not offered at baseline, but in 2023 we sent invitations for consent to return of actionable genetic
31	findings to participants. We generated exome sequence data from 4,198 participants, and used the ACMG
32	v3.2 list of 81 genes, ClinVar review and pathogenicity status, plus manual curation, to develop a pipeline
33	to identify potentially actionable variants. We identified 104 individuals (2.5%) carrying 108 actionable
34	genotypes at 39 variants in 23 genes, and validated these. Working with the NHS clinical genetics service,
35	which provided genetic counselling and clinical verification of the research results, and after expert clinical
36	review, we notified 64 consenting participants (or their next of kin) of their actionable genotypes. Ten
37	actionable variants across seven genes (BRCA1, BRCA2, ATP7B, TTN, KCNH2, MUTYH, GAA) have risen 50
38	to >3,000-fold in frequency through genetic drift in ancestral island localities. Viking Genes is one of the
39	first UK research cohorts to return actionable findings, providing an ethical and logistical exemplar of
40	return of results. The genetic structure in the Northern Isles of Scotland, with multiple founder effects,
41	provides a unique opportunity for a tailored approach to primary and secondary prevention through
42	genetic screening.

43

44 Keywords

45 Return of results, actionable variant, founder effect, exomes, Orkney, Shetland

46 Introduction

47	Where exome or genome sequencing is clinically indicated, the opportunity arises to report additional
48	incidental findings with the aim of diagnosis and pre-emptive clinical intervention. The American College
49	of Medical Genetics and Genomics (ACMG) has led this approach and annually updates a benchmark list of
50	genes for report ¹ . The list currently has 81 genes, which meet strict criteria: there must be strong evidence
51	that certain variants within the gene cause disease, and there must be effective medical intervention (for
52	example screening or medication) which can be offered to the carrier. The great majority of the genes are
53	associated with either inherited cancer predisposition, cardiovascular risk or metabolic diseases. These
54	conditions are mostly inherited in an autosomal dominant fashion, but variants in genes causing
55	autosomal recessive disease which are only actionable if homozygous or compound heterozygous are also
56	present in the ACMG v3.2 list. Although there has not yet been universal international adoption of this
57	approach, the ACMG list is the most widely used.
58	The consent obtained from participants in many research cohorts to date, including UK Biobank $\left({\sf UKB} ight)^2$,
59	does not allow the return of results about actionable variants (AVs) or genotypes. However, some newer
60	US cohorts, such as All of Us, are committed to making their research results, including hereditary disease
61	risk, accessible to participants ³ . Geisinger's MyCode Community Health Initiative provides a model for
62	"genome-first" care ⁴ , and an international policy on return of results acknowledges the potential medical
63	benefits to the individuals who are participating in genomics research ⁵ .
64	The populations of the Northern Isles of Scotland – the Orkney and Shetland archipelagos - are the most
65	genetically isolated of all British and Irish populations, with the highest degree Norse admixture, and an
66	enrichment of rare and low frequency functional variants ⁶⁻⁹ . Viking Genes (viking.ed.ac.uk) comprises a set
67	of Northern and Western Isles population cohort studies, aiming to explore genetic causes of disease – the
68	Orkney Complex Disease Study (ORCADES), and VIKING I, II and III. ORCADES ⁹ and VIKING I ¹⁰ together
69	contain a rich data resource of more than 4,000 deeply phenotyped and exome sequenced research
70	subjects, nearly all with three or four grandparents from Orkney, or Shetland, respectively. In total, Viking
71	Genes has over 10,000 participants, all of whom consented to analysis of their DNA, and to be contacted
72	at a later date in connection with future ethically approved studies. We have previously reported founder

variants in *KCNH2*, *BRCA1* and *BRCA2* in Shetland and Orkney populations¹⁰⁻¹², with variants tracing back

74 to individual island ancestries.

- 75 In Viking Genes, all cohort members were offered the option of consent to return of actionable genetic
- results. Building on a method developed by Kelly *et al*¹³ to screen 130,048 adults in the Geisinger MyCode
- project, we used the ACMG v3.2 list¹ and variant classification information from the public database
- 78 ClinVar¹⁴ to code automated filters to identify potential actionable variants within 4,198 members of the
- 79 Viking Genes cohort. Here, we describe the analysis pipeline, summarize actionable results, the process of
- 80 returning these, and some challenges associated with implementation of these procedures at scale. We
- 81 provide evidence of multiple drifted actionable founder variants that could form the basis for a future
- 82 targeted Northern Isles population genetic screening programme.
- 83

84 Subjects and Methods

85 Research Volunteer Recruitment and DNA Collection

86 Recruitment to ORCADES took place from 2005-2011¹¹, and to Viking I (Viking Health Study – Shetland)

- 87 from 2013-2015¹⁰. Blood or occasionally saliva samples from participants were collected, processed and
- stored using standard operating procedures and managed through a laboratory information management
- 89 system at the Edinburgh Clinical Research Facility, University of Edinburgh. Recruitment to VIKING II and
- 90 VIKING III took place online from January 2020 to March 2023¹⁵.
- 91 Viking Genes Pedigree Information
- 92 Records of the births, marriages and deaths in Orkney and Shetland are held at the General Register Office
- 93 for Scotland (New Register House, Edinburgh). These records, along with relationship information
- 94 obtained from study participants, Orkney and Shetland family history societies, and genealogies available
- 95 online, were used to construct pedigrees of study participants using RootsMagic software (S&N Genealogy
- 96 Supplies), which was then amended to reflect the genetic kinship between individuals using genotype
- 97 data.
- 98 Genotyping

99 DNA	from all partic	ipants was used fo	r genome-wide	genotyping of	on the GSA	BeadChip	(Illumina)) at the
--------	-----------------	--------------------	---------------	---------------	------------	----------	------------	----------

- 100 Regeneron Genetics Center. Monomorphic genotypes and genotypes with more than 2% of missingness
- and Hardy-Weinberg equilibrium (HWE) $p<10^{-6}$ were removed, as well as individuals with more than 3% of
- 102 missingness.
- 103 Exome Sequencing
- 104 Quality controlled exome sequence data sets were prepared at the Regeneron Genetics Center, following
- 105 the process detailed for UKB², with 94.6% of targeted bases having >20X coverage.
- 106 Pipeline Development
- 107 To find carriers of actionable variants, we first extracted all variants that map to genes in the ACMG v3.2
- 108 list from the whole exome sequences (WES)¹. These variants were annotated with the dbsnp version 151
- using the bcftools 1.9 annotate function, using CHROM, POS, ID, REF, ALT columns. The dbsnp 151 data was
- downloaded from https://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606_b151_GRCh38p7/VCF/ (00-
- All.vcf.gz file) in March 2022. To assess their pathogenicity, these variants were then merged with the
- 112 ClinVar data. The variant_summary.txt.gz file of the Clinvar data was downloaded on 18th March 2024,
- 113 from https://ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/. Merging by chromosome, position
- 114 (genome build GRCh38), reference (REF) and alternate (ALT) alleles was necessary, since rsids can be
- 115 multiallelic containing multiple variants at the same genomic position, including different nucleotide
- substitutions, for example tri-allelic SNPs (A>C, A>G) as well as indels, and therefore merging solely by
- 117 rsids might result in merging different variants.

Some of the variants present in the exomes were not identical to mutations listed in ClinVar, but result in the same amino-acid change as variants in ClinVar and thus the same consequence, commonly a frameshift with comparable functional effects. Therefore, we also merged the variants from the WES with ClinVar data based on the change of the amino-acid that the variant causes, instead of the CHR, POS, REF, ALT. Furthermore, if the following hypothetical indel occurred, TCATCTA > TCATCTCTA, it could be named either as c.4insCT or c.5insTC or c.6insCT, causing problems for merging the data using either of the two approaches. This is illustrated by the real variant rs886044536, *TTN* c.93396 93400del AGCTT

- 125 ([MIM: 188840], Results). This is a deletion: GCCAAGCTAAGACT > GCCAAGACT which can be rendered
- either as GCCAAG [CTAAG/*] ACT or as GCC [AAGCT/*] AAGACT.
- 127 After merging, we next filtered the output using the ClinVar annotations to retain only pathogenic or likely
- 128 pathogenic variants (P/LP), that had status 1 star or higher, that is with assertion of pathogenicity.
- 129 Moreover, the variant class had to match the disease-causing variant classes for that gene, e.g. only loss-
- 130 of-function (truncating) variants for titin (*TTN*). Variants were also subject to manual review before listing
- 131 as potentially actionable.
- 132 Whole Genome Sequencing
- 133 Whole genome sequencing (WGS) data is available for 1,300 members of the ORCADES cohort¹⁶ and 500
- 134 members of the Viking I cohort¹⁷. These datasets were used for look-ups, as part of the verification
- 135 process of the actionable variant results obtained from exome sequencing.
- 136 Sanger Sequencing
- 137 Pre-designed primer pairs for PCR and Sanger sequencing were selected from a collection that covers over
- 138 95% of human coding exons (Primer Designer, ThermoFisher Scientific). If validated primers were not
- available, primer pairs were designed using Primer3 software (ThermoFisher Scientific) and checked using
- 140 UCSC In Silico PCR¹⁸. A standard protocol for PCR and Sanger sequencing on an Applied Biosystems 3730xl
- 141 Genetic Analyser was applied across all samples. Output files were analysed using Sequencher DNA
- sequence analysis software version 5.4.6 (Gene Codes Corporation).
- 143 Validation of heterozygous short insertions/deletions (indels) can be challenging with Sanger sequencing.
- 144 Although still considered the gold standard, the sequencing ladders derived from, for example, the
- deleted and non-deleted alleles become out of synchronicity with one another (by the length of the indel
- in base-pairs), leading to double sequence after the indel in each direction. Illumina short read
- sequencing, as used to generate the exome data, does not suffer from this problem. A further issue is that
- 148 certain indels with short repeats within or near them (or in low complexity DNA) can be rendered in
- 149 multiple ways in cDNA nomenclature, e.g. TTN c.93396_93400delAGCTT (see above). More common are
- 150 single base indels altering the length of homopolymers, which can be annotated as a change at any
- 151 position in, for example, the polyA tract. Chromosome positions are affected in the same way, and so

152 when interrogating ClinVar, we performed a secondary merge using the protein sequence nomenclature,

- to pick up such instances.
- 154 Clinical review of potentially actionable genotypes
- 155 All potentially actionable variants and genotypes presented in Table S1 other than those noted as not
- determined were discussed with the NHS clinical team in order to agree suitability for return of results to
- 157 participants. Local clinical knowledge in NHS Grampian was used as part of this review process.
- 158 Electronic Health Record (EHR) Data Linkage
- 159 This work used data provided by patients and collected by the NHS as part of their care and support,
- 160 reused with permission from Public Health Scotland. NHS routine datasets linked to ORCADES and VIKING
- 161 I participants in July 2021, including SMR01, the general/acute hospital inpatient and day case dataset of
- episode level data, and SMR00, outpatient appointments and attendances, were accessed using a secure
- 163 process, as described previously¹¹.

164

- 165 Results
- 166 Exome sequencing and validation

167 Exome sequences were generated from 4,198 participants from the Viking Genes cohort using industry-

168 standard protocols as described in the Methods section. The exome sequence calls are of high quality, but

- 169 it is important to verify them in the research laboratory, before considering the process of notifying a
- potential carrier. We therefore attempted to validate 149 potential actionable variant genotypes: 77 by
- 171 Sanger sequencing, 48 by WGS and 24 by both sequence analysis methods. The total of 149 includes a

number of heterozygous carriers of recessive variants in genes on the ACMGv3.2 list. 147 out of the 149

assessed were validated (98.7%). Notably, both of the variants that failed (one by Sanger sequencing

- alone, and one by both Sanger sequencing and WGS) were only 2 kb apart in the same gene, MSH2 [MIM:
- 175 609309]. Manual review of the exome read stacks suggests that these variants are both false positives,
- 176 with low read numbers and increased noise: they were not included in the total counts of actionable
- 177 variants found.

One variant, in *DES* [MIM: 125660], c.973C>T, was found to be most likely a somatic mosaic in the sample
of venous blood and so was not included in our counts and not returned. In Sanger sequencing from
forward and reverse strands, only a very weak T was observed, and the read counts in WGS were 19 C and
1T. In 85X exome data, the total read counts (sum of forward and reverse) are 72C, 13T, for a variant allele
distribution of 15%. *Pipeline for identification of potential actionable variants*

- 184 Exome sequence data from 2,090 ORCADES participants (820 male and 1,270 female) and 2,108 VIKING I
- 185 participants (843 male and 1,265 female) passed all sequence and genotype quality control thresholds
- 186 (Methods). The data were run through our pipeline (Methods), a key component of which is the ClinVar
- 187 resource (www.ncbi.nlm.nih.gov/clinvar/). ClinVar aggregates information about genomic variation and its
- 188 relationship to human health and allocates a clinical significance category to each variant¹⁴.
- 189 In total, 59 potential actionable variants were observed, consisting of 27 singletons (Supplemental Table
- 190 S1) and 32 non-singleton variants (Tables 1 and 2). Half of the singleton variants (13/27) were observed in
- 191 participants with one non-islander parent, and a further 4/27 were in volunteers with one non-islander
- 192 grandparent, for a total of 63% of singletons with at least one quarter non-Northern Isles DNA. The
- remaining 10 singletons presumably arose by mutation in the last few generations and are thus very rare,
- 194 or were brought into the islands by non-parental events. The variants were found in 26 different genes.
- 195 For three of these genes, BTD [MIM: 609019], CASQ2 [MIM: 114251] and RPE65 [MIM: 180069], each
- 196 carrier only had a single copy of a variant that acts recessively, thus not an actionable genotype. In this
- 197 paper we are careful to distinguish between actionable variants (from the ACMG list) and actionable
- 198 genotypes, the combinations of such variants which are actionable, for example compound heterozygotes
- or homozygotes for autosomal recessive conditions. Altogether, using the 81-gene ACMG 3.2 list, we
- 200 observed actionable genotypes for 104 individuals (2.5% of the population) carrying 108 actionable
- 201 genotypes at 39 of the variants, across 23 genes. No X-linked actionable variants were found.
- 202 The level of support for each review status in ClinVar decreases from four star downwards
- 203 (https://www.ncbi.nlm.nih.gov/clinvar/docs/review_status). The great majority of the actionable variants

204	we found were 3 (reviewed by expert panel) or 2 (criteria provided, multiple submitters, no conflicts) star
205	(Table S1). Three of the non-singleton autosomal dominant actionable variants (Table 1) had a review
206	status in ClinVar of 1 star, all of which had a single submitter. The paucity of submissions often indicates
207	rarity of the variant, which in turn makes assessment of pathogenicity and hence actionability more
208	challenging.
209	Actionable genotype co-occurrences
210	We identified four individuals with actionable genotypes in two separate genes (Table 3). We expect some
211	such co-occurrences because of independent assortment, and we should see these according to the
212	product of the allele frequencies of the variants in question. If one or both have drifted upwards in
213	frequency, more will be seen. We found that two of these four Viking Genes individuals had AVs in two
214	different cancer susceptibility genes, while two had actionable genotypes in a cancer susceptibility gene
215	and a metabolic gene.
216	Drifted actionable variants in Northern Isles populations
217	The isolated Northern Isles populations carry different sets of rare variants compared to cosmopolitan
218	populations. In total, 10 actionable variants across 7 genes (BRCA1 [MIM: 113705], BRCA2 [MIM:600185],
219	ATP7B [MIM: 606882], TTN [MIM: 188840], KCNH2 [MIM: 152427], MUTYH [MIM: 604933], GAA [MIM:
220	606800]) have risen in frequency by at least 50-fold through the action of genetic drift in the Northern
221	Isles (Table 4). These include results published previously on a BRCA1 breast and ovarian cancer
222	predisposition variant that is 470-fold more common in Orkney than in the UKB ¹¹ , a <i>KCNH2</i> Long QT
223	Syndrome variant that is ~90-fold more common in Shetland ¹⁰ , and a pathogenic <i>BRCA2</i> variant ~155-fold
224	more common in Shetland ¹² .
225	Most actionable variants in the ACMG list have a dominant mode of inheritance and so are actionable if
226	heterozygous, but some are only considered actionable if present in two copies. Table 4 includes five
227	drifted variants in Northern Isles populations that act recessively (also listed in Table 2). These are in
228	ATP7B (three drifted variants segregating in our cohorts), MUTYH and GAA. Wilson Disease [MIM:
229	277900] is a disorder of copper metabolism, caused by variants in the copper transporting ATPase gene
230	ATP7B. The marked discrepancy between the "genetic prevalence" in populations and the number of

231 clinically diagnosed cases of Wilson Disease is probably due both to reduced penetrance of many ATP7B mutations, and failure to diagnose patients with this highly treatable disorder¹⁹. We identified three 232 233 founder effects on recessive ATP7B Wilson disease variants, two in Shetland, which gives rise to 234 substantial risk of homozygosity or compound heterozygosity. The combined allele frequency in 235 Shetlanders is 0.8%. Together with five other alleles segregating at lower frequencies, the sum 236 Pathogenic/Likely Pathogenic (P/LP) allele frequency is 1.12%; thus about 1/45 Shetlanders are carriers of 237 P/LP ATP7B variants. Under random mating, this predicts about 1/8000 will be homozygotes or compound 238 heterozygotes, at risk of being affected. Indeed, one homozygote for the drifted variant c.3007G>A was 239 found. There is a founder effect on a recessive MUTYH variant (c.1130C>T) in Orkney (0.86% carriers, 70x more 240 241 common than UKB), causing MYH-associated polyposis [MIM: 608456] (Table 4). While not increased in 242 frequency compared to other populations, there are two further MUTYH variants segregating in the 243 Orcadian population, bringing the combined carrier frequency to 2.9%. This suggests that 1/35 Orcadians 244 are carriers and, assuming random mating among Orcadians, an expectation that ~1/5000 will be at risk of 245 MYH-associated polyposis. Consistent with this, we did observe a compound heterozygote in the Orkney 246 data. 247 Finally, there are also founder effects in Shetland on two dominant loss-of-function titin (TTN) variants, 248 increasing the risk of dilated cardiomyopathy [MIM: 604145] (Table 4). One of these, c.93396 93400del, is 249 >3,000-fold more common in Shetland than in UKB, where there is only a single instance in 917,682 250 alleles. Together with a third returnable TTN variant that does not meet our thresholds to be defined as 251 drifted, the combined allele frequency is 0.5%, meaning 1/100 Shetlanders are carriers. In total, we 252 observed 24 carriers of TTN loss-of-function (LoF) variants (23 of which are accounted for by these three 253 alleles). 254 An ultra-rare drifted titin variant 255 The penetrance of the TTN alleles included in ClinVar as pathogenic or likely pathogenic is variable and age 256 related. However, the deletion of 5 nucleotides c.93396 93400del causes a frameshift, which creates a

10

premature translational stop signal (p.Trp31134*), predicted to result in an absent or disrupted protein

258 product. This variant is in the A-band of the TTN gene. Truncating variants in the A-band of TTN are 259 significantly overrepresented in patients with dilated cardiomyopathy (DCM), and are considered to be likely pathogenic for the disease²⁰. TTN truncating variants (TTNtv) located in exons highly expressed in 260 261 the heart (proportion spliced in [PSI]>0.9, or hiPSI), such as this one, increase the odds of DCM by 11-19-262 fold²¹. This variant has therefore been classified as Likely Pathogenic in ClinVar. We examined data from 263 347 individuals ascertained with DCM and found to carry hiPSI TTNtv in DCM cohort studies from Europe, USA and Australia, and also interrogated data from TTNty carriers in the UKB²², the Geisinger MyCode 264 Biobank and the PennMedicine Biobank (168 affected with DCM, 2,409 unaffected)²¹. In total we observed 265 1,200 distinct hiPSI TTNtv in 2,094 individuals. The c.93396 93400del variant was observed twice (1 in 266 267 UKB and 1 in MyCode), both times in individuals without a diagnosis of DCM. The variant was not observed in the 100,000 Genomes Project²³ (670 DCM cases, 62,330 non-DCM participants) or All of Us²⁴ 268 (245,460 total participants, of whom 125,860 were reported as European heritage), and therefore can be 269 270 considered ultra-rare. 271 Analysis of linked data from the EHR for cardiomyopathy (ICD-10 code I42), atrial fibrillation (ICD-10 I48) 272 or heart failure (ICD-10 I50) shows that the 16 carriers of the drifted TTN variant c.93396 93400del we 273 identified in VIKING I are nearly four times more likely (P=0.02, Fisher's exact test) to have an inpatient or 274 day patient record for cardiomyopathy (1/16), atrial fibrillation (2/16) or heart failure (2/16) than non-275 carriers (4/16 carriers have entries for at least one of these conditions, i.e. a nominal combined 276 penetrance of 25%, versus a prevalence of 6.8% in 4,133 individuals without TTN LoF variants). Analysis of 277 ECG data collected in the VIKING 1 recruitment clinic from 15 of the carriers also shows an over-278 representation of features such as first degree atrioventricular block (3/15) or right bundle branch block 279 (4/15), affecting a total of 7 carriers. In one Shetland TTN c.93396 93400del family investigated clinically, 280 the condition has typically been detectable on echocardiography around age 30, but symptoms have not 281 developed until later. One patient required a cardiac resynchronisation therapy-defibrillator, while 282 another is asymptomatic despite an abnormal echocardiogram in their late 50s. Together with the 7 283 entries in ClinVar submitted to date, we now report this further direct evidence for pathogenicity of this ultra-rare drifted TTN variant. 284

285 Impact of sub-population gene pools

286	The drifted variants are not shared between the two archipelagos, except <i>TTN</i> p.Gln22507Ter, which is
287	observed in Shetland among individuals with recent Orcadian ancestry; and MUTYH p.Pro377Leu, for
288	which the Shetland carriers have no recent Orcadian ancestry. This latter variant may have been
289	introduced to the Northern Isles more than once, or there may be unrecorded non-parental events
290	connecting the Orcadian and Shetlandic kindreds.
291	The great majority of these actionable variants can be traced back to individual isles within Orkney or
292	Shetland, or in some cases individual parishes: 13-15 ancient geographic, legal, and religious subdivisions
293	of the Mainlands of Orkney and Shetland (Figure 1). Among published variants, 95% of carriers of the
294	drifted BRCA1 variant traced their genealogies to Westray, in the North Isles of Orkney ¹¹ , while 78% of the
295	drifted BRCA2 variant carriers trace back to Whalsay, an isle in Shetland ¹² . Likewise, drifted KCNH2 variant
296	carriers from Viking Genes and NHS Clinical Genetics ¹⁰ trace back either to the parish of Aithsting in the
297	West Mainland of Shetland or Unst in the North Isles of Shetland (Figure 1 and Table 4).
298	Among the drifted variants reported here, 80% of the carriers of the most drifted ATP7B variant have
299	genealogies going back to Burra Isle, Shetland and there is also a strong founder effect on the most highly
300	drifted TTN variant c.93396_93400del, this time in Yell, in the North Isles of Shetland, with 100% of
301	carriers tracing their family trees back to there. Further fine scale, within-archipelago population
302	structuring of clinically important variants is observed in Westray, in the North Isles of Orkney, with
303	another ATP7B variant having drifted to high frequencies there, and 100% of carriers tracing pedigrees
304	there, similarly to a <i>MUTYH</i> variant, where 60% of carriers have Westray genealogies; indeed, we
305	observed a compound heterozygote with ancestry from that isle.
306	Genetic down-drift
307	It is more difficult to quantify which variants have drifted down in frequency, but the near absence of
308	familial hypercholesterolaemia (FH) [MIM: 143890 and MIM:144010] variants is notable, with only one
309	carrier across >4,000 subjects. This <i>LDLR</i> [MIM: 606945] variant was observed in Shetland and is the
310	known p.C163Y West of Scotland founder variant ²⁵ ; it may have been brought to the isles by recent gene
311	flow from Mainland Scotland; no FH variants were observed in Orkney. No P/LP APOB [MIM:107730] or

312 PCSK9 [MIM: 607786] variants were observed. Significantly fewer volunteers from the Northern Isles

313 carried FH variants than observed in European ancestry participants from the UKB (P<0.0001, Fisher's

- exact test). The carrier frequency in the Northern Isles (1/4198) is more than 10-fold lower than that in
- 315 UKB European ancestry subjects $(1/288)^{26}$.

316 The Return of Results (RoR) process

317 With reference to the Association of Clinical Genomic Science (ACGS) guidelines

318 (https://www.acgs.uk.com/media/12533/uk-practice-guidelines-for-variant-classification-v12-2024.pdf)

and local clinical knowledge, four variants in a total of 10 genotype carriers were not deemed returnable

320 by the NHS clinical team (Table 5 and Table S1). Our next goal was to implement a process of return of

321 results (RoR) to carrier participants, summarised in Figure 2. Key principles include: the use of informed

322 consent; respecting the right not to know; checking the research results as far as possible before sharing a

potentially actionable variant ID; decisions on whether to return a variant result taken by NHS clinical

324 experts; counselling provided through the NHS, and verification of all the research results in an accredited

325 clinical laboratory. The consent form and RoR participant information sheets sent to cohort members are

- 326 provided as supplemental information. Frequently asked questions about return of results are available
- 327 for participants on the study website at <u>https://viking.ed.ac.uk/for-viking-genes-volunteers/faqs/return-</u>

328 <u>of-results</u>

329 We obtained a favourable opinion from the Research Ethics Committee to return results of genotypes that

have the potential to improve the health of the individuals carrying them. We subsequently obtained

further permission to contact male carriers of pathogenic *BRCA1* variants. This was justified by the fact

that although there is no clinical action to be taken with respect to the letter recipient, the information

could be of value to their female relatives, who may not be Viking Genes research participants. There are

13 male carriers of the *BRCA1* p.V1736A variant in the ORCADES cohort¹¹ and none in VIKING I, so addition

of these participants increases the total number of actionable genotypes from 108 to 121. Since there are

four individuals with two actionable genotypes each (Table 3), this corresponds to a total of 117 total

337 actionable genotype carriers (Table 5).

We further obtained ethical permission to offer actionable results to the next of kin of deceased participants, if we found any that might have been relevant to the health of the participant who died, and therefore potentially their family, during our research (Figure 2). To date, six next of kin have provided their consent to receive this information, with one actionable genotype disclosed.

342 The process we have implemented is in good accordance with a checklist of components for return of

results developed by an interdisciplinary panel of European experts²⁷. In Viking Genes, the return of

344 medically actionable genetic results to participants is optional, i.e. an opt-in approach. This has legal,

345 philosophical, and ethical foundations, to allow patient autonomy and the right not to know. This is

achieved at three separate points in the process of implementation (Figure 2). Letters containing results

347 are only sent with the consent of the recipient. Upon receipt, the participant can decline any further

investigation by not contacting the NHS about the research finding. Finally, after genetic counselling, the

patient can decide not to have the research result confirmed in a clinical setting. It should also be noted

350 that a participant can get in touch with Viking Genes at any time to request to change the consent they

351 gave about RoR, in either direction, or to withdraw from the study. The research team communicates with

352 Viking Genes volunteers by regular newsletters and social media, and invites them to complete occasional

research surveys. A subset of participants in the study forms the public - participant involvement (PPI)

group. We therefore aim to ensure both that understanding of the opportunity to receive results is high,

and the processes we are implementing have the support of the study participants and the populations

they are drawn from.

357 Initial outcomes from issuing RoR letters

The text of the letters alerting the volunteer to the research result is written in lay language, agreed by the research and NHS teams, and the template document was given a favourable opinion by the Research Ethics Committee. The NHS clinic team is not made aware of the identity of the research participants, but approves return of the variants, which are also noted in the letters. Letters were not sent to all carrier participants at one time. Instead, the 64 RoR letters issued (Table 5) were posted over the course of almost exactly one year. This was designed to prevent the NHS clinics from being overwhelmed, but has meant that outcomes are still being accumulated. For example, it is too early to tally the number of family

365	members contacted by cascade testing from each index case. In the NHS, each index case on average
366	leads to three subsequent cascade tests, half of which are positive ²⁸ . In the case of the Shetland <i>BRCA2</i>
367	founder variant c.517-2A>G, a total of 56 people were eligible for cascade letters from just 5 consented
368	carriers in Viking Genes, suggesting a higher level of knowledge of family structure among our
369	participants. We observe that RoR letter recipients take a variable length of time to decide whether to
370	contact the NHS, and not all choose to do so.
371	In all three of the previously reported actionable founder variants ¹⁰⁻¹² , we identified carriers in our
372	research populations who could not have been ascertained from oral history-based cascade testing.
373	Likewise, many of the index cases described here were found to be in family groups not previously
374	recorded by the clinical geneticists. Out-patient NHS EHR data showed that only 9% of our carriers had
375	interacted with clinical genetics, compared with 3.6% of the non-carriers, a 2.5-fold increase (P<0.002, χ^2).
376	This provides further evidence that a substantial number of the research participants who received a
377	return of results letter were previously unaware of the genomic medicine finding, and have the
378	opportunity for preventative medical intervention as a result of the Viking Genes return of results
379	programme.
380	

381 Discussion

382 Survey of Actionable Variants

383 We observed actionable genotypes for 39 autosomal actionable variants, 34 dominant and 5 recessive,

and no X-linked variants. Ten founder variants showed strong enrichment, having risen >50-fold in

frequency in Orkney or Shetland, while otherwise commonly seen variants, notably those causing familial

386 hypercholesterolaemia, were at least ten-fold lower in frequency. Importantly, both TTN and ATP7B

387 contain multiple drifted variants, which sum together to even higher frequencies of (likely) pathogenic

388 variation.

389 The ten actionable variants which have drifted up to much higher frequencies in Orkney or Shetland than

in the general UK population mostly have a clear origin in a particular parish or isle within the Northern

391 Isles, 200 or more years ago, highlighting the continuing clinical importance of these historic sub-

population gene pools. As is the case with other genetic isolate populations²⁹, the combination of multiple
founder variants can result in a significant summed population frequency, sometimes in conjunction with
non-drifted variants. At the same time, other variants have drifted towards loss, balancing the genetic
burden of disease risk.

396 *Comparisons with other populations surveyed for actionable variants*

397 Overall, these two UK isolate populations have a similar percentage of actionable genotypes (2.5%),

398 compared to cosmopolitan populations worldwide. However, the number carrying one or more actionable

399 genotypes depends on the gene list, rules applied (including bespoke curation) and date of analysis. The

400 ACMG list of recommendations of genes and phenotypes is updated annually, whereas ClinVar is designed

to enable the ongoing evolution and development of knowledge regarding variations and associated

402 phenotypes, and its website is updated weekly. The status of a variant, particularly if observed rarely

403 worldwide, may therefore change over time as more data are submitted, interpreted and reported in

404 ClinVar. This makes it challenging to compare our Viking Genes actionable variant carrier percentage with

405 populations reported in other publications. In the first 50,000 exome sequences from the UKB population

406 cohort, an actionable genotype figure of 2.0% was reported². However, that analysis used v2.0 of the

407 ACMG list³⁰, containing 59 genes, rather than the 81 in v3.2 that were surveyed here. Similarly, a figure of

408 2.8% can be calculated from the DiscovEHR study³¹ and 2.3% in Iceland³², using the ACMG list v2.0.

409 Another way to compare with studies in other populations is to use the ACMG 2.0 (59 gene) list to assess

410 our data in the Northern Isles population, in which case the percentage with actionable genotypes drops

411 to 1.4%.

The inclusion of *HFE* [MIM: 613609] p.Cys282Tyr homozygotes, in later versions of the list, would on its own increase the percentage of actionable genotype carriers in the UKB from 2.0% to 2.6%. This is based on the *HFE* variant having a reported homozygous frequency of 0.6%, or 1 in 156, in the UKB³³. We therefore show here that the Northern Isles populations have an AV percentage that is in a similar range to the rest of the population of the UK as sampled in the UKB, to the DiscovEHR study of people in Pennsylvania, USA, and to the Icelandic population (4.0% in the most recent analysis, including manual

418 curation)³², but much lower than that reported for the Old Order Amish of Pennsylvania³⁴.

419	We identified a sufficient number of carriers to provide specific evidence for pathogenicity of one drifted
420	variant in <i>TTN</i> , c.93396_93400del, p.Trp31134*. A total of 44 genes were recently asserted to be
421	implicated in non-syndromic Dilated Cardiomyopathy (DCM) by the ClinGen DCM Gene Curation Expert
422	Panel ³⁵ . <i>TTN</i> is one of 11 genes with definite evidence, and featured in a gene-based analysis of
423	penetrance and clinical phenotype in 18,665 UKB participants ³⁶ . A sub-analysis for genes including <i>TTN</i>
424	revealed DCM or early DCM features in 45.4% of cases ³⁶ . Moreover, significant excess mortality was
425	observed among carriers of <i>TTN</i> truncating variants in Dutch founder pedigrees, driven by subjects ≥60
426	years ³⁷ .
427	Return of Results to Research Volunteers - Benefits and Challenges
428	The return of results processes that we successfully implemented for Viking Genes participants as
429	described here were somewhat more straightforward than they would be in cosmopolitan populations,
430	due to the reduced number of different actionable variants in the ancestral populations of the Northern
431	Isles of Scotland, and the high support for and trust in scientific research in these communities.
432	Nonetheless, the processes and experiences of returning actionable genetic results in Viking Genes are
433	directly relevant as an exemplar (especially in the UK) for other research cohorts interested in the
434	feasibility and logistics of the return of actionable results to their participants. Our recent recruitment to a
435	new cohort study, VIKING II, was eligible to people of Northern Isles ancestry regardless of domicile ¹⁵ . At
436	the outset of recruitment, VIKING II offered the option of consent to return of selected clinically
437	actionable results. This option was chosen by an overwhelming majority (98%), 6,054 of the 6,178
438	participants who consented and completed the study questionnaire. This is in good agreement with
439	several other studies that also show strong support for receiving actionable findings, both in theory and in
440	practice ^{38,39} . These views may mean that the return of actionable genetic findings from research will in
441	future become the default practice ³⁹ . However, the costs, harms and benefits of returning actionable
442	results are still at an early stage of being fully characterized.
443	For some diseases in the ACMG list, there can often be a long delay before accurate diagnosis, due to the
444	overlap of symptoms with other more prevalent conditions. Examples we have found in Viking Genes
445	include Pompe disease [MIM: 232300], caused by a deficiency of the enzyme acid alpha-glucosidase

(GAA), which can lead to nerve and muscle problems, Wilson disease [MIM: 277900], caused by copper 446 447 overload, and the iron overload condition hereditary haemochromatosis [MIM: 235200] (HFE). Early 448 diagnosis and thus early intervention can have an impact on future quality of life. Furthermore, in addition 449 to the medical intervention available for each actionable result, a clearer diagnosis/etiology following the 450 return of results can also be of value, for those already affected, particularly for conditions like 451 cardiomyopathy which have complex symptoms and presentation. Increased awareness of these 452 otherwise rare conditions among healthcare workers in the Northern Isles could lead to decreased times to diagnosis, with concomitant benefits to patients. 453 454 Cross-sectional approaches, for example to understand the penetrance of rare-variants in cardiomyopathy-associated genes, can provide valuable data⁴⁰, and genome-first evaluation at scale can 455 enable new diagnoses missing from clinical healthcare⁴¹. However, the scientific literature is only just 456 457 beginning to provide insight into how the ACMG guidelines have been translated into precision health 458 outcomes for the recipients of the findings: for some genes benefits clearly outweigh harms, while for 459 others there is little evidence as yet⁴²⁻⁴⁴. This is likely to gather pace in the near future, as more large scale initiatives such as All of Us³, the Healthy Oregon Project⁴⁵ and the Colorado Center for Personalized 460 461 Medicine⁴⁶ implement the return of actionable results. Furthermore, disease manifestation, healthcare 462 outcomes and costs of disclosure have recently been described for actionable findings in a UK setting from the Genomics England 100,000 Genomes Project⁴⁷. Genomics England returned results for actionable 463 464 genotypes in 13 genes within the 81 genes on the ACMG3.2 list, for hereditary cancer syndromes and 465 familial hypercholesterolaemia, plus carrier status for cystic fibrosis ([MIM: 219700], not on the ACMG 466 list). Due to a lack of consensus on benefit versus harm and the challenges of reduced penetrance, 467 Genomics England chose not to inform carriers of actionable genotypes increasing the risk of Long QT 468 syndrome, cardiomyopathies, aortopathies, further inherited cancers, metabolic diseases and the most frequent genetic disease, hereditary haemochromatosis (www.genomicsengland.co.uk/initiatives/100000-469

470 genomes-project/additional-findings).

471 Jensson *et al*³² found shorter median survival among persons carrying actionable genotypes than among
472 non-carriers, in Iceland. Specifically, they report that carrying an actionable genotype in a cancer gene on

473	the ACMG list was associated with life span that was three years shorter than that among noncarriers,
474	with causes of death among carriers attributed primarily to cancer-related conditions. Furthermore, while
475	many studies have demonstrated the diagnostic and therapeutic value of exome or whole genome
476	sequencing in critically ill paediatric cases, a recent study shows that the diagnostic utility of exome
477	sequencing in critically ill adults is similar, largely due to uncovering variants in medically actionable
478	genes ⁴⁸ .
479	Our data highlight the clinical relevance of local genetic sub-populations, as most of the founder variants
480	are also associated with one or other parish or isle, with deep genealogies linking most carriers to
481	ancestors from there (notwithstanding ancestral non-parental events which obscure the connection
482	between genetics and geography). Within each archipelago, it is natural that historic barriers to marriage
483	in the form of storm-prone, strongly tidal ocean and sea channels and sounds, have given rise to
484	subpopulation gene pools or micro-isolates ^{7,49} . Within the main islands, the parishes are sometimes
485	separated by low hills or sea firths, and sometimes not, but marriage records show they were
486	demographically important over the centuries.
487	Population Screening Opportunities
488	Population screening in a clinical context is currently available in some populations that show founder
489	effects, such as an NHS programme offering BRCA-testing to those with Jewish ancestry
490	(https://www.nhsjewishbrcaprogramme.org.uk/). Charitable organisations are also increasingly making
491	specific genetic tests available to populations of higher risk. Examples include improving the prevention
492	and diagnosis of Jewish genetic disorders in the UK (<u>https://www.jnetics.org/</u>) and the provision of postal
493	tests for genetic haemochromatosis (<u>https://www.haemochromatosis.org.uk/</u>).
494	Our estimates of the frequency of the BRCA1 and BRCA2 actionable variants in Westray and Whalsay,
495	respectively, $(1/19 \text{ and } 1/43)^{12}$ show that the local gene pool frequencies can be much higher than the
496	archipelago-wide frequencies. This in turn suggests that individuals with ancestry from islands such as Yell,
497	Burra and Westray are at higher risk of being carriers than the Shetland- or Orkney-wide data suggest. The
498	ability to target testing to those with an origin in a particular parish may improve the cost-effectiveness of
499	future screening. At the same time, with increasing movement, younger generations and inhabitants of

the towns of Kirkwall and Lerwick (and of course the diasporas outside the Northern Isles) tend to have

501 more mixed ancestry, so the importance of these micro-isolates is waning.

502 We report four actionable genotype co-occurrences. Many more instances in other populations are likely

- to be uncovered in the future, as genetic analyses move from limited gene panels towards WES and WGS.
- 504 A recent review, for example, describes Multi-locus Inherited Neoplasia Allele Syndrome (MINAS), which

⁵⁰⁵ refers to individuals with germline pathogenic variants in two or more cancer susceptibility genes⁵⁰.

506 We have not investigated LoF variants that may be present in our data, but which are not reported in

507 ClinVar. There may be potentially important ultra-rare variants in this class, which warrants future

research. Furthermore, clinically relevant variants that lie outside of exomes, and structural variants, may

509 be uncovered in subsequent research. However, except for the most drifted variants, the assessment of

510 pathogenicity will always be limited by the modest numbers of carriers likely to be found in our cohorts.

511 We also note that the high levels of engagement and knowledge of kinship led to higher uptake of cascade

testing, and thus a higher-than-expected demand on clinical services, compared to previous cascade

513 testing statistics reported in the NHS²⁸.

514 Studies of population genetic structure using unselected genome-wide markers^{7,51} are not always

515 considered relevant for clinical genetics. However, a number of reports now demonstrate the

516 consequences of such population structure for clinical genetics at the population level. A case in point is

517 the Irish Travellers, shown to be a distinct population isolate of Irish origin⁵² with their own suite of

518 Mendelian conditions at high frequencies⁵³. Similarly, the genetic isolation of Orkney and Shetland has

been shown to translate into clinically important differences at the population level, from the earliest

520 studies of Northern Isles genetics, showing a founder effect on the SOD1 [MIM: 147450] p.D90A allele⁵⁴,

to novel Mendelian conditions⁵⁵⁻⁵⁷, and distinct blood group/isozyme⁵⁸ and uniparental⁶ markers. More
 recently, numerous founder effects, both on Mendelian recessive alleles⁸, and on dominant actionable

523 variants¹⁰⁻¹² have been described.

524 Orcadians and Shetlanders thus belong to a group of European-heritage populations, including Ashkenazi 525 Jews and Irish Travellers, where high frequencies of important clinical variants have arisen from genetic

526 drift, with concomitant simplification of the gene pools providing valuable opportunities for population-

527 wide, cost-effective targeted genetic screening.

528

529 Data and Code Availability Statement

- 530 There is neither Research Ethics Committee approval, nor consent from Viking Genes participants, to
- 531 permit open release of the individual level research data underlying this study. The datasets generated
- and analysed during the current study are therefore not publicly available. Instead, the research data
- and/or DNA samples are available from accessQTL@ed.ac.uk on reasonable request, following approval by
- 534 the Data Access Committee and in line with the consent given by participants. The ClinVar-exome pipeline
- 535 code is available on GitHub (<u>https://github.com/viking-genes/clinvar_pipeline</u>). Frequencies for the ten
- 536 drifted variants reported here were derived from the UK Biobank Whole Genome Sequencing (WGS)
- 537 project and were obtained from the publicly available UK Biobank Allele Frequency Browser
- 538 (<u>https://afb.ukbiobank.ac.uk/</u>), which was generated by the WGS consortium under the UK Biobank
- 539 Resource (project ID 52293).

540 Acknowledgments

- 541 This work was funded by the Medical Research Council University Unit award to the MRC Human Genetics
- 542 Unit, University of Edinburgh, MC_UU_00007/10 and a Wellcome Trust Institutional Translational
- 543 Partnership Award (University of Edinburgh 222060/Z/20/Z -PIII031). LK was supported by an RCUK
- 544 Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). ORCADES was
- supported by the Chief Scientist Office of the Scottish Government (CZB/4/276 and CZB/4/710), a Royal
- 546 Society URF to JFW, and Arthritis Research UK. JSW was supported by the Medical Research Council (UK),
- 547 Sir Jules Thorn Charitable Trust (21JTA), British Heart Foundation (RE/18/4/34215), and the NIHR Imperial
- 548 College Biomedical Research Centre. This research has been conducted using the UK Biobank Resource
- under Application Numbers 47602 and 19655.
- 550 Emily Weiss and Reka Nagy assembled the Orkney pedigree, and Barbara Gray the Shetland pedigree,
- 551 using records at the General Register Office, the Shetland Family History Society, and study information,
- 552 building on earlier pedigree work by Ruth McQuillan and Jim Wilson. Sanger sequencing was performed

553	by the technical services team at the MRC Human Genetics Unit. We thank the NHS Grampian clinical
554	genetics team and the Viking Genes research team (in particular David Buchanan, Rachel Edwards and
555	Craig Sinclair) for their contributions to the implementation of the return of results process. Finally, we
556	thank the people of the Northern and Western Isles for their involvement in and ongoing support for our
557	research.
558	Author Contributions
559	SMK managed the project and drafted the manuscript. LK created and implemented the ClinVar-exome
560	pipeline, with input and support from KJ, and analysed the exome datasets. MDM updated the pipeline.
561	CD validated exome data by PCR and Sanger sequencing of genomic DNA. MH validated exome data by
562	analysis of WGS data. SMK, ZM and JFW planned the RoR methodology. ZM and JD provided information
563	on the clinical epidemiology of the Northern Isles and clinically reviewed the variants to be reported. JSW,
564	SLZ and PKT interpreted phenotype data in cardiomyopathy variant carriers. GT and ARS conceived and
565	managed the Viking Genes exome sequencing. ZM led the NHS RoR clinical team, which included genetic
566	counsellors EC and LS, who discussed actionable results with participants. JFW is the Chief Investigator of
567	Viking Genes, was awarded funding to implement the work, analysed the data and helped draft the
568	manuscript. All authors provided input and feedback on drafts of the manuscript.
569	Ethical Approval
570	Eligible participants were recruited to Viking Genes, NHS Lothian South East Scotland Research Ethics
571	Committee reference 19/SS/0104. Research participants gave informed consent for research procedures
572	including DNA sequencing (mandatory) and return of actionable results (optional).
573	
574	For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to
575	any Author Accepted Manuscript version arising from this submission.
576	
577	Supplemental Files

578 Supplemental Table S1 All actionable variants reported by our ClinVar pipeline.

- 579 Supplemental Information RoR Participant Information Sheet (PIS), RoR Consent Form and RoR PIS for
- 580 Next of Kin.
- 581

582 Declaration of Interests

- 583 AS and GT are employees and/or stockholders of Regeneron Genetics Center or Regeneron
- 584 Pharmaceuticals. LK is an employee of BioAge Labs and holds share options. JSW has received research
- 585 support from Bristol Myers Squibb, and has acted as a consultant for MyoKardia, Pfizer, Foresite Labs,
- 586 Health Lumen, and Tenaya Therapeutics.
- 587

588 References

- Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H.,
 Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2023). ACMG SF v3.2 list for reporting of
 secondary findings in clinical exome and genome sequencing: A policy statement of the American
 College of Medical Genetics and Genomics (ACMG). Genet Med 25, 100866.
 10.1016/j.gim.2023.100866.
- 5942.Van Hout, C.V., Tachmazidou, I., Backman, J.D., Hoffman, J.D., Liu, D., Pandey, A.K., Gonzaga-595Jauregui, C., Khalid, S., Ye, B., Banerjee, N., et al. (2020). Exome sequencing and characterization596of 49,960 individuals in the UK Biobank. Nature 586, 749-756. 10.1038/s41586-020-2853-0.
- Venner, E., Muzny, D., Smith, J.D., Walker, K., Neben, C.L., Lockwood, C.M., Empey, P.E., Metcalf,
 G.A., Kachulis, C., All of Us Research Program Regulatory Working, G., et al. (2022). Whole genome sequencing as an investigational device for return of hereditary disease risk and
 pharmacogenomic results as part of the All of Us Research Program. Genome Med 14, 34.
 10.1186/s13073-022-01031-z.
- Schwartz, M.L.B., McCormick, C.Z., Lazzeri, A.L., Lindbuchler, D.M., Hallquist, M.L.G., Manickam,
 K., Buchanan, A.H., Rahm, A.K., Giovanni, M.A., Frisbie, L., et al. (2018). A Model for Genome-First
 Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a
 Large Research Cohort. Am J Hum Genet *103*, 328-337. 10.1016/j.ajhg.2018.07.009.
- 6065.Lewis, A.C.F., Knoppers, B.M., and Green, R.C. (2021). An international policy on returning607genomic research results. Genome Med 13, 115. 10.1186/s13073-021-00928-5.
- 608 6. Wilson, J.F., Weiss, D.A., Richards, M., Thomas, M.G., Bradman, N., and Goldstein, D.B. (2001).
 609 Genetic evidence for different male and female roles during cultural transitions in the British Isles.
 610 Proc Natl Acad Sci U S A *98*, 5078-5083. 10.1073/pnas.071036898.
- 611 7. Gilbert, E., O'Reilly, S., Merrigan, M., McGettigan, D., Vitart, V., Joshi, P.K., Clark, D.W., Campbell,
 612 H., Hayward, C., Ring, S.M., et al. (2019). The genetic landscape of Scotland and the Isles. Proc Natl
 613 Acad Sci U S A *116*, 19064-19070. 10.1073/pnas.1904761116.
- 6148.Halachev, M., Gountouna, V.E., Meynert, A., Tzoneva, G., Shuldiner, A.R., Semple, C.A., and615Wilson, J.F. (2024). Regionally enriched rare deleterious exonic variants in the UK and Ireland. Nat616Commun 15, 8454. 10.1038/s41467-024-51604-2.
- 617 9. McQuillan, R., Leutenegger, A.L., Abdel-Rahman, R., Franklin, C.S., Pericic, M., Barac-Lauc, L.,
- 618 Smolej-Narancic, N., Janicijevic, B., Polasek, O., Tenesa, A., et al. (2008). Runs of homozygosity in 619 European populations. Am J Hum Genet *83*, 359-372. 10.1016/j.ajhg.2008.08.007.
- 620 10. Kerr, S.M., Klaric, L., Halachev, M., Hayward, C., Boutin, T.S., Meynert, A.M., Semple, C.A.,
- 521 Tuiskula, A.M., Swan, H., Santoyo-Lopez, J., et al. (2019). An actionable KCNH2 Long QT Syndrome

622 variant detected by sequence and haplotype analysis in a population research cohort. Sci Rep 9, 623 10964.10.1038/s41598-019-47436-6. Kerr, S.M., Cowan, E., Klaric, L., Bell, C., O'Sullivan, D., Buchanan, D., Grzymski, J.J., van Hout, C.V., 624 11. 625 Tzoneva, G., Shuldiner, A.R., et al. (2023). Clinical case study meets population cohort: 626 identification of a BRCA1 pathogenic founder variant in Orcadians. Eur J Hum Genet 31, 588-595. 627 10.1038/s41431-023-01297-w. 628 12. Kerr, S.M., Klaric, L., Muckian, M.D., Cowan, E., Snadden, L., Tzoneva, G., Shuldiner, A.R., 629 Miedzybrodzka, Z., and Wilson, J.F. (2024). Two founder variants account for over 90% of pathogenic BRCA alleles in the Orkney and Shetland Isles in Scotland. European Journal of Human 630 631 Genetics. 10.1038/s41431-024-01704-w. 632 13. Kelly, M.A., Leader, J.B., Wain, K.E., Bodian, D., Oetjens, M.T., Ledbetter, D.H., Martin, C.L., and 633 Strande, N.T. (2021). Leveraging population-based exome screening to impact clinical care: The 634 evolution of variant assessment in the Geisinger MyCode research project. Am J Med Genet C 635 Semin Med Genet 187, 83-94. 10.1002/ajmg.c.31887. 636 Landrum, M.J., Chitipiralla, S., Brown, G.R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, 14. K., Liu, C., et al. (2020). ClinVar: improvements to accessing data. Nucleic Acids Res 48, D835-637 638 D844. 10.1093/nar/gkz972. 639 15. Kerr, S., Edwards, R., Buchanan, D., Dean, J., Miedzybrodzka, Z., and Wilson, J. (2023). VIKING II, a 640 Worldwide Observational Cohort of Volunteers with Northern Isles Ancestry. International Journal 641 of Population Data Science 8. 10.23889/ijpds.v8i1.2121. 642 16. Gilly, A., Klaric, L., Park, Y.C., Png, G., Barysenka, A., Marsh, J.A., Tsafantakis, E., Karaleftheri, M., 643 Dedoussis, G., Wilson, J.F., and Zeggini, E. (2022). Gene-based whole genome sequencing meta-644 analysis of 250 circulating proteins in three isolated European populations. Mol Metab 61, 645 101509. 10.1016/j.molmet.2022.101509. 646 17. Halachev, M., Meynert, A., Taylor, M.S., Vitart, V., Kerr, S.M., Klaric, L., Consortium, S.G.P., Aitman, 647 T.J., Haley, C.S., Prendergast, J.G., et al. (2019). Increased ultra-rare variant load in an isolated 648 Scottish population impacts exonic and regulatory regions. PLoS Genet 15, e1008480. 649 10.1371/journal.pgen.1008480. 650 18. Raney, B.J., Barber, G.P., Benet-Pages, A., Casper, J., Clawson, H., Cline, M.S., Diekhans, M., Fischer, C., Navarro Gonzalez, J., Hickey, G., et al. (2024). The UCSC Genome Browser database: 651 652 2024 update. Nucleic Acids Res 52, D1082-D1088. 10.1093/nar/gkad987. 653 19. Wallace, D.F., and Dooley, J.S. (2020). ATP7B variant penetrance explains differences between 654 genetic and clinical prevalence estimates for Wilson disease. Hum Genet 139, 1065-1075. 655 10.1007/s00439-020-02161-3. 656 20. Roberts, A.M., Ware, J.S., Herman, D.S., Schafer, S., Baksi, J., Bick, A.G., Buchan, R.J., Walsh, R., 657 John, S., Wilkinson, S., et al. (2015). Integrated allelic, transcriptional, and phenomic dissection of 658 the cardiac effects of titin truncations in health and disease. Sci Transl Med 7, 270ra276. 659 10.1126/scitranslmed.3010134. Haggerty, C.M., Damrauer, S.M., Levin, M.G., Birtwell, D., Carey, D.J., Golden, A.M., Hartzel, D.N., 660 21. 661 Hu, Y., Judy, R., Kelly, M.A., et al. (2019). Genomics-First Evaluation of Heart Disease Associated 662 With Titin-Truncating Variants. Circulation 140, 42-54. 10.1161/CIRCULATIONAHA.119.039573. 663 22. Backman, J.D., Li, A.H., Marcketta, A., Sun, D., Mbatchou, J., Kessler, M.D., Benner, C., Liu, D., 664 Locke, A.E., Balasubramanian, S., et al. (2021). Exome sequencing and analysis of 454,787 UK 665 Biobank participants. Nature 599, 628-634. 10.1038/s41586-021-04103-z. 666 23. Investigators, G.P.P., Smedley, D., Smith, K.R., Martin, A., Thomas, E.A., McDonagh, E.M., Cipriani, 667 V., Ellingford, J.M., Arno, G., Tucci, A., et al. (2021). 100,000 Genomes Pilot on Rare-Disease 668 Diagnosis in Health Care - Preliminary Report. N Engl J Med 385, 1868-1880. 669 10.1056/NEJMoa2035790. 670 24. Bick, A.G., Metcalf, G.A., Mayo, K.R., Lichtenstein, L., Rura, S., Carroll, R.J., Musick, A., Linder, J.E., 671 Jordan, I.K., Nagar, S.D., et al. (2024). Genomic data in the All of Us Research Program. Nature 672 627, 340-346. 10.1038/s41586-023-06957-x. 673 25. Lee, W.K., Haddad, L., Macleod, M.J., Dorrance, A.M., Wilson, D.J., Gaffney, D., Dominiczak, M.H., 674 Packard, C.J., Day, I.N., Humphries, S.E., and Dominiczak, A.F. (1998). Identification of a common

675		low density lipoprotein receptor mutation (C163Y) in the west of Scotland. J Med Genet 35, 573-
676		578. 10.1136/jmg.35.7.573.
677	26.	Gratton, J., Humphries, S.E., and Futema, M. (2023). Prevalence of FH-Causing Variants and Impact
678		on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-
679		Brief Report. Arterioscler Thromb Vasc Biol 43, 1737-1742. 10.1161/ATVBAHA.123.319438.
680	27.	Vears, D.F., Hallowell, N., Bentzen, H.B., Ellul, B., Nost, T.H., Kerasidou, A., Kerr, S.M., Th
681		Mayrhofer, M., Mezinska, S., Ormondroyd, E., et al. (2023). A practical checklist for return of
682		results from genomic research in the European context. Eur J Hum Genet <i>31</i> , 687-695.
683		10.1038/s41431-023-01328-6.
684	28.	Woodward, E.R., Green, K., Burghel, G.J., Bulman, M., Clancy, T., Lalloo, F., Schlecht, H., Wallace,
685		A.J., and Evans, D.G. (2022). 30 year experience of index case identification and outcomes of
686		cascade testing in high-risk breast and colorectal cancer predisposition genes. Eur J Hum Genet
687		<i>30</i> , 413-419. 10.1038/s41431-021-01011-8.
688	29.	Hamel, N., Kotar, K., and Foulkes, W.D. (2003). Founder mutations in BRCA1/2 are not frequent in
689		Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 4, 7. 10.1186/1471-2350-
690		4-7.
691	30.	Kalia, S.S., Adelman, K., Bale, S.J., Chung, W.K., Eng, C., Evans, J.P., Herman, G.E., Hufnagel, S.B.,
692		Klein, T.E., Korf, B.R., et al. (2017). Recommendations for reporting of secondary findings in clinical
693		exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American
694		College of Medical Genetics and Genomics. Genet Med 19, 249-255. 10.1038/gim.2016.190.
695	31.	Dewey, F.E., Murray, M.F., Overton, J.D., Habegger, L., Leader, J.B., Fetterolf, S.N., O'Dushlaine, C.,
696		Van Hout, C.V., Staples, J., Gonzaga-Jauregui, C., et al. (2016). Distribution and clinical impact of
697		functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science 354.
698		10.1126/science.aaf6814.
699	32.	Jensson, B.O., Arnadottir, G.A., Katrinardottir, H., Fridriksdottir, R., Helgason, H., Oddsson, A.,
700		Sveinbjornsson, G., Eggertsson, H.P., Halldorsson, G.H., Atlason, B.A., et al. (2023). Actionable
701		Genotypes and Their Association with Life Span in Iceland. N Engl J Med 389, 1741-1752.
702		10.1056/NEJMoa2300792.
703	33.	Pilling, L.C., Tamosauskaite, J., Jones, G., Wood, A.R., Jones, L., Kuo, CL., Kuchel, G.A., Ferrucci, L.,
704		and Melzer, D. (2019). Common conditions associated with hereditary haemochromatosis genetic
705		variants: cohort study in UK Biobank. BMJ <i>364,</i> k5222. 10.1136/bmj.k5222.
706	34.	Lynch, M.T., Maloney, K.A., Pollin, T.I., Streeten, E.A., Xu, H., Regeneron Genetics, C., Shuldiner,
707		A.R., Van Hout, C.V., Gonzaga-Jauregui, C., and Mitchell, B.D. (2021). The burden of pathogenic
708		variants in clinically actionable genes in a founder population. Am J Med Genet A 185, 3476-3484.
709		10.1002/ajmg.a.62472.
710	35.	Jordan, E., Peterson, L., Ai, T., Asatryan, B., Bronicki, L., Brown, E., Celeghin, R., Edwards, M., Fan,
711		J., Ingles, J., et al. (2021). Evidence-Based Assessment of Genes in Dilated Cardiomyopathy.
712		Circulation 144, 7-19. 10.1161/CIRCULATIONAHA.120.053033.
713	36.	Shah, R.A., Asatryan, B., Sharaf Dabbagh, G., Aung, N., Khanji, M.Y., Lopes, L.R., van Duijvenboden,
714		S., Holmes, A., Muser, D., Landstrom, A.P., et al. (2022). Frequency, Penetrance, and Variable
715		Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK
716		Biobank Participants. Circulation 146, 110-124. 10.1161/CIRCULATIONAHA.121.058143.
717	37.	Jansen, M., Baas, A.F., van Spaendonck-Zwarts, K.Y., Ummels, A.S., van den Wijngaard, A.,
718		Jongbloed, J.D.H., van Slegtenhorst, M.A., Lekanne Deprez, R.H., Wessels, M.W., Michels, M., et al.
719		(2019). Mortality Risk Associated With Truncating Founder Mutations in Titin. Circ Genom Precis
720		Med <i>12</i> , e002436. 10.1161/circgen.118.002436.
721	38.	Middleton, A., Morley, K.I., Bragin, E., Firth, H.V., Hurles, M.E., Wright, C.F., Parker, M., and study,
722		D.D.D. (2016). Attitudes of nearly 7000 health professionals, genomic researchers and publics
723		toward the return of incidental results from sequencing research. Eur J Hum Genet 24, 21-29.
724		10.1038/ejhg.2015.58.
725	39.	Schupmann, W., Miner, S.A., Sullivan, H.K., Glover, J.R., Hall, J.E., Schurman, S.H., and Berkman,
726		B.E. (2021). Exploring the motivations of research participants who chose not to learn medically

727		actionable secondary genetic findings about themselves. Genet Med 23, 2281-2288.
728		10.1038/s41436-021-01271-1.
729	40.	McGurk, K.A., Zhang, X., Theotokis, P., Thomson, K., Harper, A., Buchan, R.J., Mazaika, E.,
730		Ormondroyd, E., Wright, W.T., Macaya, D., et al. (2023). The penetrance of rare variants in
731		cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for
732		secondary findings. Am J Hum Genet <i>110</i> , 1482-1495. 10.1016/j.ajhg.2023.08.003.
733	41.	Forrest, I.S., Duffy, A., Park, J.K., Vy, H.M.T., Pasquale, L.R., Nadkarni, G.N., Cho, J.H., and Do, R.
734		(2024). Genome-first evaluation with exome sequence and clinical data uncovers underdiagnosed
735		genetic disorders in a large healthcare system. Cell Rep Med, 101518.
736		10.1016/j.xcrm.2024.101518.
737	42.	Sapp, J.C., Facio, F.M., Cooper, D., Lewis, K.L., Modlin, E., van der Wees, P., and Biesecker, L.G.
738		(2021). A systematic literature review of disclosure practices and reported outcomes for medically
739		actionable genomic secondary findings. Genet Med 23, 2260-2269. 10.1038/s41436-021-01295-7.
740	43.	Blout Zawatsky, C.L., Shah, N., Machini, K., Perez, E., Christensen, K.D., Zouk, H., Steeves, M., Koch,
741		C., Uveges, M., Shea, J., et al. (2021). Returning actionable genomic results in a research biobank:
742		Analytic validity, clinical implementation, and resource utilization. Am J Hum Genet 108, 2224-
743		2237. 10.1016/j.ajhg.2021.10.005.
744	44.	Clayton, E.W., Smith, M.E., Anderson, K.C., Chung, W.K., Connolly, J.J., Fullerton, S.M., McGowan,
745		M.L., Peterson, J.F., Prows, C.A., Sabatello, M., and Holm, I.A. (2023). Studying the impact of
746		translational genomic research: Lessons from eMERGE. Am J Hum Genet 110, 1021-1033.
747		10.1016/j.ajhg.2023.05.011.
748	45.	O'Brien, T.D., Potter, A.B., Driscoll, C.C., Goh, G., Letaw, J.H., McCabe, S., Thanner, J., Kulkarni, A.,
749		Wong, R., Medica, S., et al. (2023). Population screening shows risk of inherited cancer and
750		familial hypercholesterolemia in Oregon. Am 1 Hum Genet <i>110</i> , 1249-1265.
751		10.1016/i.aihg.2023.06.014.
752	46	Wiley LK Shortt LA Roberts ER Lowery L Kudron E Lin M Mayer D Wilson M
753	101	Brunetti T.M. Chavan S. et al. (2024). Building a vertically integrated genomic learning health
754		system: The biobank at the Colorado Center for Personalized Medicine, Am I Hum Genet 111, 11-
755		23 10 1016/i aibg 2023 12 001
756	47	Nolan I Buchanan I Taylor I Almeida I Bedenham T Blair F Broadgate S Butler S
757		Careaux A Craft L et al (2023) Secondary (additional) findings from the 100 000 Genomes
758		Project: disease manifestation, healthcare outcomes and costs of disclosure. Genet Med, 101051
759		10 1016/i gim 2023 101051
760	48	Gold I Krinke CM Center R.G. BioBank P.M. and Drivas T.G. (2024) Universal Exome
761	101	Sequencing in Critically III Adults: A Diagnostic Yield of 25% and Race-Rased Disparities in Access to
762		Genetic Testing medRxiv 2024 2003 2011 24304088 10 1101/2024 03 11 24304088
763	49	O'Dushlaine C McQuillan B Weale M E Crouch D L Johansson A Aulchenko Y Franklin
764	-5.	CS Polasek O Euchsherger C Convin A et al (2010) Genes predict village of origin in rural
765		Europe Fur I Hum Genet 18, 1269-1270, 10,1038/eilbg 2010, 92
766	50	McGuigan A Whitworth I Andreou A Hearn T Genomics England Research C Tischkowitz
767	50.	M. and Maher, E.R. (2022). Multilocus Inherited Neonlasia Allele Syndrome (MINAS): an undate
768		Fur L Hum Genet 30, $265-270$, 10, $1038/c/11/31-021-01013-6$
769	51	Leclie S. Winney B. Hellenthal G. Davison D. Boumertit A. Dav T. Hutnik K. Bovryik E.C.
705	51.	Cupliffe B. Wellcome Trust Case Control C. et al. (2015) The fine scale genetic structure of the
770		Pritich nonulation Natura 510, 200, 214, 10, 1028/natura14220
//1 770	E 2	Gilbert E. Carmi S. Ennic S. Wilson J.E. and Cavalleri G.L. (2017). Conomic insidets into the
772 277	52.	nonulation structure and history of the Irich Travellars, Sci Pon 7, 42197, 10, 1029/gran42197
775	F 2	population structure and history of the first fraveners. Sci kep 7, 42167. 10.1056/srep42167.
775 775	در.	Eynen, J.A., Crushen, L., Lambert, D.M., Dynne, N., Gorman, K., King, W.D., Green, A., O Sullivan, S., Browno, E., Hughos, L., et al. (2018). Catalogue of inhoritod disorders found among the Wish
775 770		Drowne, F., Hugnes, J., et al. (2016). Catalogue of Innented disorders round among the Irish Travellar population - Mod Const EE 222,220, 10,1120 / modes and 2017,104074
//0 777	E 4	Moleh S.C. and Moars C.W. (1972). Constitutionaria of human indexthered evidence in the
///	54.	Westray Island of the Orknove, Lum Harad 22, 28, 41, 10, 1150/000152465
778		westray island of the Urkneys. Hum Hered 22, 38-41. $10.1159/000152465$.
//9	55.	Kennie, A.G. (1983). The Whaisay cataract. Trans Ophthalmol Soc U K (1962) <i>103 (Pt 5),</i> 530-531.

- 780 56. Muir, V.M. (1978). Tylosis in the Orkney islands. J Biosoc Sci *10*, 1-6.
- 781 10.1017/s0021932000011408.
- 782 57. Rugg, E.L., Common, J.E., Wilgoss, A., Stevens, H.P., Buchan, J., Leigh, I.M., and Kelsell, D.P. (2002).
 783 Diagnosis and confirmation of epidermolytic palmoplantar keratoderma by the identification of

mutations in keratin 9 using denaturing high-performance liquid chromatography. Br J Dermatol
 146, 952-957. 10.1046/j.1365-2133.2002.04764.x.

786 58. Roberts, D.F. (1986). Who are the Orcadians? Anthropologischer Anzeiger 44, 93-104.

787



Fair Isle 789 790 Figure 1 Isles and parishes of Orkney and Shetland. Each archipelago consists of a larger island called the 791 Mainland, with surrounding smaller isles. Both island groups can be divided into 4-6 larger areas, such as 792 West Shetland (known locally as the West side) or the West Mainland of Orkney, which in turn are 793 organised into 25 parishes or isles. Founder effects are usually concentrated in one parish/isle or in one of 794 the larger contiguous areas. W&W, Whiteness & Weisdale; Tin, Tingwall; Ler, Lerwick; St A, St. Andrews; 795 K&StO, Kirkwall & St. Ola; Orp, Orphir; Ste, Stenness; Str, Stromness; San, Sandwick (Orkney); Bir, Birsay; 796 Evi, Evie; Ren, Rendall; Fir, Firth; Har, Harray.

- 797
- 798



800 Figure 2. Overview of Viking Genes return of results. Processes implemented by the Viking Genes

- 801 research team are boxed with no shading; processes implemented by the NHS clinical team are shaded.
- 802 PIS, participant information sheet (see Supplemental information).

category	disease	gene	С.	p.	clin sig	actionable	consequence	LoF	star
	breast-ovarian cancer, familial	BRCA1	c.5207T>C	p.Val1736Ala	pathogenic	A∥ P and LP	missense	0	3
		BRCA2	c.517-2A>G		pathogenic	A∥ P and LP	splice acceptor	1	3
cancer	Lynch syndrome	MSH6	c.3261dup	p.Phe1088fs	pathogenic	A∥ P and LP	frameshift	1	3
	attenuated familial adenomatous polyposis	APC	c.154C>T	p.Gln52Ter	pathogenic	All P and LP	stop gain	1	2
	multiple endocrine neoplasia	RET	c.2410G>A	p.Va 804Met	P/LP	All P and LP	missense	0	2
metabolic	hereditary transthyretin amyloidosis	TTR	c.262A>T	p.lle88Leu	P/LP	A∥ P and LP	missense	0	2
	long QT syndrome	KCNH2	c.1750G>A	p.Gly584Ser	P/LP	A∥ P and LP	missense	0	2
		SCN5A	c.4716C>T	p.Gly1572=	P/LP	A∥ P and LP	splice donor	1	2
		TTN	c.1558dupA*	p.Thr520fs	LP	only LOF	frameshift	1	1
cardiovascular	dilated cardiomyopathy	TTN	c.67519C>T	p.Gln22507Ter	LP	only LOF	stop gain	1	1
		TTN	c.88837A>T	p.Lys29613Ter	P/LP	only LOF	stop gain	1	2
		TTN	c.93396_93400del	p.Ala31133_Trp31134insTer	P/LP	only LOF	frameshift	1	2
	vascular Ehlers-Danlos syndrome	COL3A1	c.944G>C*	p.Gly315Ala	LP	All P and LP	missense	0	1

Table 1 Summary of non-singleton autosomal dominant actionable variants in the cohort of 4,198 participants. The diseases are grouped into the categories of cancer, metabolic and cardiovascular. c., coding sequence change; p., protein sequence change; clin sig, clinical significance according to ClinVar; LP, likely pathogenic; P/LP, pathogenic/likely pathogenic; actionable, variant categories considered to be actionable; LOF, loss of function; consequence, the molecular consequence of the variant; star, ClinVar star status. TTN c.1558dupA does not appear in ClinVar, so the star status and clinical significance are given for a variant causing the identical amino-acid change. *These variants were not considered actionable by the NHS Clinical Genetics team and were not returned.

category	disease	gene	с.	p.	clin sig	actionable	consequence	LoF	star
		MUTYH	c.452A>G	p.Tyr151Cys	P/LP	P and LP (2 var)	missense	0	2
cancer	MYH-associated polyposis	MUTYH	c.1103G>A	p.Gly368Asp	P/LP	P and LP (2 var)	missense	0	2
		MUTYH	c.1130C>T	p.Pro377Leu	pathogenic	P and LP (2 var)	missense	0	2
		ATP7B	c.122A>G	p.Asn41Ser	P/LP	P and LP (2 var)	missense	0	2
		ATP7B	c.1745_1746de	p.IIe582fs	P/LP	P and LP (2 var)	frameshift	1	2
	·	ATP7B	c.1772G>A	p.Gly591Asp	P/LP	P and LP (2 var)	missense	0	2
		ATP7B	c.2605G>A	p.Gly869Arg	P/LP	P and LP (2 var)	missense	0	2
	Wilson disease	ATP7B	c.2662A>C	p.Thr888Pro	P/LP	P and LP (2 var)	missense	0	2
		ATP7B	c.2930C>T	p.Thr977Met	pathogenic	P and LP (2 var)	missense	0	2
		ATP7B	c.3007G>A	p.Ala1003Thr	P/LP	P and LP (2 var)	missense	0	2
		ATP7B	c.3083_3085delinsG	p.Lys1028fs	pathogenic	P and LP (2 var)	frameshift	1	2
metabolic		ATP7B	c.3207C>A	p.His1069Gln	pathogenic	P and LP (2 var)	missense	0	2
	biotinidase deficiency	BTD	c.1308A>C	p.Gln436His	P/LP	P and LP (2 var)	missense	0	2
	biotimuase dentiency	BTD	c.1552C>T	p.Arg518Cys	pathogenic	P and LP (2 var)	missense	0	2
	hereditary haemochromatosis	HFE	c.845G>A	p.Cys282Tyr	pathogenic	C282Y homs only	missense	0	2
	Pompe disease	GAA	c.841C>T	p.Arg281Trp	LP	P and LP (2 var)	missense	0	3
		GAA	c.1194+3G>C		LP	P and LP (2 var)	splice region	0	3
		GAA	c.1210G>A	p.Asp404Asn	pathogenic	P and LP (2 var)	missense	0	3
		GAA	c.2238G>C	p.Trp746Cys	pathogenic	P and LP (2 var)	missense	0	3

Table 2 Summary of non-singleton autosomal recessive actionable variants in the cohort of 4,198 participants. The diseases are grouped into the categories of cancer and metabolic. c., coding sequence change; p., protein sequence change; clin sig, clinical significance according to ClinVar; LP, likely pathogenic; P/LP, pathogenic/likely

pathogenic; actionable, variant categories considered to be actionable; LOF, loss of function; consequence, the molecular consequence of the variant; star, ClinVar star status; 2 var, 2 variants must be present, so either homozygous or compound heterozygous for the P/LP variant; homs only indicates that only homozygotes for the named variant should be reported.

Gene 1	variant ID	inheritance	genotype	Gene 2	variant ID	inheritance	genotype
BRCA1	c.5207T>C	AD	het	PMS2	c.137G>T	AD	het
BRCA2	c.6275_6276del	AD	het	MSH6	c.742C>T	AD	het
BRCA2	c.517-2A>G	AD	het	GAA	c.841C>T	AR	hom
BRCA2	c.5073dupA	AD	het	HFE	c.845G>A	AR	hom

Table 3. Actionable genotype co-occurrences. AD, autosomal dominant; het, heterozygous; hom, homozygous.

gene	С.	p.	disease	inher	maf.ork	ork/ukb	maf.shet	shet/ukb	group	origin
BRCA1	c.5207T>C	p.Val1736Ala	Hereditary	AD	0.00478	470	0	0	Orkney	Westray
BRCA2	c.517-2A>G		breast ovarian cancer	AD	0	0	0.00237	155	Shetland	Whalsay
ATP7B	c.3083_3085delinsG	p.Lys1028fs		AR	0	0	0.00475	180	Shetland	Burra
ATP7B	c.3007G>A	p.Ala1003Thr	Wilson disease	AR	0	0	0.00356	350	Shetland	Sandsting/Lunnasting/ Delting
ATP7B	c.1772G>A	p.Gly591Asp		AR	0.00215	66	0	0	Orkney	Westray
TTN	c.93396_93400del	p.Ala31133_Trp 31134insTer	Dilated	AD	0	0	0.00380	3700	Shetland	Yell
TTN	c.67519C>T	p.Gln22507Ter	cardiomyopathy	AD	0.00048	700	0.00071	470	Orkney	West Mainland
КСМН2	c.1750G>A	p.Gly584Ser	Long QT syndrome	AD	0	0	0.00119	90	Shetland	Aithsting, Unst
митүн	c.1205C>T	p.Pro377Leu	MYH-associated polyposis	AR	0.00431	70	0.00047	8	Orkney	Westray
GAA	c.1210G>A	p.Asp404Asn	Pompe disease	AR	0.00287	74	0	0	Orkney	St. Andrews

Table 4 Founder effects on ten actionable variants in Orkney and Shetland. Drifted variants were defined as actionable variants with an increase in frequency over 50-fold higher than UKB, a pedigree origin before *c*. 1800 CE and a minor allele count of \geq 5. For UKB, we used the allele frequency browser (based on ~490k WGS). c., complementary DNA position and nucleotide change; p., protein position and amino-acid change; inher, inheritance; maf.ork, minor allele frequency in Orkney; ork/ukb, fold uplift in frequency in Orkney over UKB; maf.shet, minor allele frequency in Shetland; shet/ukb, fold uplift in frequency in Shetland over UKB; group, island group the variant has drifted upwards in; origin, subpopulation (parish, isle or region) where the variant arose (by tracing back pedigrees) or has become particularly common.

Actionable genotype carriers	Category
64	Results letters sent, including one to Next of Kin
33	Not consented - did not reply to Return of Results consent invitation
8	Deceased and no request from Next of Kin
2	Answered no to Return of Results consent invitation
10	Not deemed returnable by NHS
117	TOTAL ACTIONABLE GENOTYPE CARRIERS, including <i>BRCA1</i> males and accounting for co-occurrences

Table 5 Summary of carriers of actionable genotypes and results returned. Consent was only sought 8-18 years

after recruitment, which is probably why 28% of actionable genotype carriers did not reply to the invitation. A

further 11% were deceased, while 2.7% replied choosing not to have return of results. NHS, National Health Service.